Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CWBRNASDAQ:EVOKNASDAQ:ONCONASDAQ:TCRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AEVOKEvoke Pharma$3.18+0.6%$2.81$1.94▼$12.32$4.75M0.16122,408 shs3,191 shsONCOOnconetix$0.07+3.6%$0.09$0.05▼$21.40$4.69M3.494.67 million shs3.30 million shsTCRTAlaunos Therapeutics$2.89+1.4%$2.26$1.31▼$13.30$4.74M-1.08135,585 shs7,166 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCWBRCohBar0.00%0.00%0.00%0.00%-46.06%EVOKEvoke Pharma-1.11%+0.49%+41.14%-36.88%-43.87%ONCOOnconetix-4.11%-0.28%+12.36%-87.85%-98.35%TCRTAlaunos Therapeutics0.00%0.00%-2.40%+72.21%-77.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/AEVOKEvoke Pharma0.3547 of 5 stars0.04.00.00.02.20.00.0ONCOOnconetix0.5857 of 5 stars0.02.00.00.03.30.80.6TCRTAlaunos Therapeutics0.4313 of 5 stars0.02.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCWBRCohBar 0.00N/AN/AN/AEVOKEvoke Pharma 0.00N/AN/AN/AONCOOnconetix 0.00N/AN/AN/ATCRTAlaunos Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AEVOKEvoke Pharma$10.25M0.46N/AN/A($9.26) per share-0.34ONCOOnconetix$1.87M2.51N/AN/A$3.01 per share0.02TCRTAlaunos Therapeutics$10K473.96N/AN/A$3.93 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/AEVOKEvoke Pharma-$7.79M-$4.40N/A∞N/A-71.32%-308.49%-53.66%5/13/2025 (Estimated)ONCOOnconetix-$37.41MN/A0.00∞N/A-2,758.89%N/A-48.09%5/19/2025 (Estimated)TCRTAlaunos Therapeutics-$35.14MN/A0.00∞N/AN/A-267.77%-209.18%5/13/2025 (Estimated)Latest CWBR, TCRT, EVOK, and ONCO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/13/2025Q4 2024EVOKEvoke Pharma-$0.25-$0.49-$0.24-$0.49$3.08 million$3.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCWBRCohBarN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/ATCRTAlaunos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCWBRCohBarN/AN/AN/AEVOKEvoke PharmaN/A1.441.39ONCOOnconetixN/A0.060.05TCRTAlaunos TherapeuticsN/A4.304.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCWBRCohBar2.47%EVOKEvoke PharmaN/AONCOOnconetix23.89%TCRTAlaunos Therapeutics27.72%Insider OwnershipCompanyInsider OwnershipCWBRCohBar6.51%EVOKEvoke Pharma2.29%ONCOOnconetix11.42%TCRTAlaunos Therapeutics5.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCWBRCohBar102.91 millionN/ANot OptionableEVOKEvoke Pharma41.49 million1.40 millionNot OptionableONCOOnconetix1264.55 million57.17 millionN/ATCRTAlaunos Therapeutics401.64 million1.52 millionNo DataCWBR, TCRT, EVOK, and ONCO HeadlinesRecent News About These CompaniesAlaunos Therapeutics announces board member resignationApril 20, 2025 | investing.comThese 3 Healthcare Stocks Show Serious Muscle Amid Trump Tariff Turmoil: Are Retail Traders Feeling Bullish?April 7, 2025 | msn.comPrecigen Terminates License Agreement With Alaunos TherapeuticsOctober 11, 2024 | marketwatch.comAfter axing its sole clinical prospect last year, Alaunos cuts ties with PrecigenOctober 11, 2024 | fiercebiotech.comAlaunos Therapeutics Ends Licensing Deal, Reassesses StrategyOctober 11, 2024 | finance.yahoo.comAlaunos Therapeutics (NASDAQ:TCRT) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comAlaunos Therapeutics (NASDAQ:TCRT) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comStella Pharma Corporation (4888.T) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comTCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024May 16, 2024 | investorplace.comRevolution Medicines: An Expensive Shot At A Massive Market OpportunityApril 12, 2024 | seekingalpha.comTCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023April 8, 2024 | investorplace.comBiora Therapeutics announces $6M registered direct offering and concurrent private placementApril 1, 2024 | msn.comSharp increase in TCRT’s short interest leads to surge in days-to-cover ratioFebruary 1, 2024 | knoxdaily.comAlaunos Therapeutics Announces 1-for-15 Reverse Stock SplitJanuary 31, 2024 | msn.comWerewolf Therapeutics Inc (HOWL)January 31, 2024 | investing.comAlaunos Therapeutics Inc [TCRT] Insider Boyle Kevin S. Sr. sells 68,014 Shares – Latest Insider ActivityJanuary 3, 2024 | knoxdaily.comAlaunos Therapeutics Stock (NASDAQ:TCRT) Dividends: History, Yield and DatesDecember 28, 2023 | benzinga.comTCRT Shares Experience Decline in ValueNovember 17, 2023 | knoxdaily.comRecap: Alaunos Therapeutics Q3 EarningsNovember 14, 2023 | benzinga.comWhy Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?November 14, 2023 | investorplace.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit2 Smart Investments to Follow Warren Buffett’s LeadBy Ryan Hasson | April 23, 2025View 2 Smart Investments to Follow Warren Buffett’s LeadAnalysts See $4,000 Gold: 3 Ways to Invest at Varied Risk LevelsBy Leo Miller | May 2, 2025View Analysts See $4,000 Gold: 3 Ways to Invest at Varied Risk LevelsCWBR, TCRT, EVOK, and ONCO Company DescriptionsCohBar NASDAQ:CWBR$0.41 0.00 (0.00%) As of 01/23/2025CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Evoke Pharma NASDAQ:EVOK$3.18 +0.02 (+0.63%) As of 01:54 PM EasternEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Onconetix NASDAQ:ONCO$0.07 +0.00 (+3.57%) As of 02:07 PM EasternOnconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.Alaunos Therapeutics NASDAQ:TCRT$2.89 +0.04 (+1.40%) As of 01:55 PM EasternAlaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
